TAK 715

Key Product Details

Product Description

TAK 715 is an inhibitor of p38 MAPK (IC₅₀ = 7.1 nM for p38 MAPKα). Also inhibits Wnt-3a-stimulated β-catenin signaling. Inhibits 22 kinases by more than 80%, including CK1δ/ε. Anti-inflammatory and anti-rheumatoid arthritis agent. Orally bioavailable.

Product Specifications for TAK 715

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for TAK 715

The following data is based on the product molecular weight 399.51.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.50 mL	12.52 mL	25.03 mL
5 mM	0.50 mL	2.50 mL	5.01 mL
10 mM	0.25 mL	1.25 mL	2.50 mL
50 mM	0.05 mL	0.25 mL	0.50 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 9 publications citing the usage of this product.

• Verkaar Inhibition of Wnt/β-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Iδ/ε. Chem.Biol. 2011 PMID: 21513885
• Miwatashi Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug: discovery of N-[4-{2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J.Med.Chem. 2005 PMID: 16162000

Product Documents for TAK 715